Monolithic Power Systems Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Monolithic Power Systems Inc trades at $1,393.27 (market cap $70.08B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: Monolithic Power Systems Inc is far larger — about 30.7× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Monolithic Power Systems Inc pays a 0.56% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| MPWR | SLS | |
|---|---|---|
Market Cap | $70.08B | $2.28B |
Volume | 480,594 | 3,128,960 |
Sector | Technology | Health |
52-Week High | $1.69K | $15.46 |
52-Week Low | $856.96 | $1.39 |
Typical Hold Time | 25 Days | — |
Enterprise Value | $68.68B | $2.15B |
Dividend Yield | 0.56% | — |
Signals from Pluang's Aura AI — not financial advice
Monolithic Power Systems (MPWR) trades at $1,425.98, down 3.24% on the day, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 24.5% net income margin and 21.98% ROE, though valuation metrics remain elevated at 87 P/E. Recent earnings beats and a manufacturing partnership with GlobalFoundries signal continued growth potential in AI and data center markets.
MPWR presents a compelling growth story driven by AI infrastructure demand, but faces valuation concerns and insider selling pressure. The stock's 88% buy rating consensus and $1,830 price target suggest 28% upside potential, though investors should weigh premium valuation against strong execution and market positioning.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →